These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 21906275)

  • 41. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice.
    Zhang Y; Zou J; Yang J; Yao Z
    Curr Alzheimer Res; 2015; 12(4):384-97. PubMed ID: 25817256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model.
    Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T
    Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro.
    Liao MC; Van Nostrand WE
    Biochemistry; 2010 Feb; 49(6):1127-36. PubMed ID: 20050683
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans.
    Lemere CA; Maier M; Jiang L; Peng Y; Seabrook TJ
    Rejuvenation Res; 2006; 9(1):77-84. PubMed ID: 16608400
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology.
    Gnoth K; Piechotta A; Kleinschmidt M; Konrath S; Schenk M; Taudte N; Ramsbeck D; Rieckmann V; Geissler S; Eichentopf R; Barendrecht S; Hartlage-Rübsamen M; Demuth HU; Roßner S; Cynis H; Rahfeld JU; Schilling S
    Alzheimers Res Ther; 2020 Nov; 12(1):149. PubMed ID: 33189132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aβ-HBc virus-like particles immunization without additional adjuvant ameliorates the learning and memory and reduces Aβ deposit in PDAPP mice.
    Jin H; Wang W; Zhao S; Yang W; Qian Y; Jia N; Feng G
    Vaccine; 2014 Jul; 32(35):4450-4456. PubMed ID: 24962758
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice.
    Wang HC; Yu YZ; Liu S; Zhao M; Xu Q
    Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tanshinone IIA reduces the risk of Alzheimer's disease by inhibiting iNOS, MMP‑2 and NF‑κBp65 transcription and translation in the temporal lobes of rat models of Alzheimer's disease.
    Jiang P; Li C; Xiang Z; Jiao B
    Mol Med Rep; 2014 Aug; 10(2):689-94. PubMed ID: 24859152
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.
    Obregon D; Hou H; Bai Y; Nikolic WV; Mori T; Luo D; Zeng J; Ehrhart J; Fernandez F; Morgan D; Giunta B; Town T; Tan J
    Neurobiol Dis; 2008 Feb; 29(2):336-53. PubMed ID: 18055209
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Development of antibodies for immunotherapy of Alzheimer's disease].
    Matsumoto SE; Jin H; Takeda K; Hasegawa Y; Motoi Y; Hattori N; Tabira T
    Rinsho Shinkeigaku; 2012; 52(11):1168-70. PubMed ID: 23196552
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of A beta plaque clearance following passive A beta immunization.
    Morgan D
    Neurodegener Dis; 2005; 2(5):261-6. PubMed ID: 16909007
    [TBL] [Abstract][Full Text] [Related]  

  • 56. β-Amyloid, cholinergic transmission, and cerebrovascular system -- a developmental study in a mouse model of Alzheimer's disease.
    Kuznetsova E; Schliebs R
    Curr Pharm Des; 2013; 19(38):6749-65. PubMed ID: 23530514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy for Alzheimer's disease.
    Morgan D
    J Intern Med; 2011 Jan; 269(1):54-63. PubMed ID: 21158978
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.
    Burbach GJ; Vlachos A; Ghebremedhin E; Del Turco D; Coomaraswamy J; Staufenbiel M; Jucker M; Deller T
    Neurobiol Aging; 2007 Feb; 28(2):202-12. PubMed ID: 16427722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism.
    Yin KJ; Cirrito JR; Yan P; Hu X; Xiao Q; Pan X; Bateman R; Song H; Hsu FF; Turk J; Xu J; Hsu CY; Mills JC; Holtzman DM; Lee JM
    J Neurosci; 2006 Oct; 26(43):10939-48. PubMed ID: 17065436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.
    Wilcock DM; Rojiani A; Rosenthal A; Subbarao S; Freeman MJ; Gordon MN; Morgan D
    J Neuroinflammation; 2004 Dec; 1(1):24. PubMed ID: 15588287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.